Joseph Siletto, MBA, is a Managing Director of Vivo Capital. Mr. Siletto focuses primarily on growth equity and private equity transactions for commercial companies. Joseph serves on the board of directors for Aerobiotix, Scientia Vascular, Seran Bioscience, HistoWiz, InBrace and is a board observer for Neocis and Minerva Surgical. He also previously represented Vivo on the board of Preventice Solutions (acquired by Boston Scientific in January 2021), Sera Prognostics, and was the interim CEO and then Chief Business Officer for Surgical Specialties (acquired by GTCR in January 2021).
Mr. Siletto has over 20 years of experience in life sciences transactions and investments as a CEO to a private company, investment banker and investor. Prior to joining Vivo, he co-founded Scion Medical, a commercial-stage, China-US cross border medical device roll-up in the interventional oncology segment which Varian Medical (NYSE: VAR) acquired in 2019. Earlier in his career, Mr. Siletto was an Investment Banker for Banc of America Securities and Cowen Inc..
He received his B.A. from Duke University and an M.B.A. from the University at California at Berkeley. Mr Siletto, studied at Beijing Language Institute and is fluent in Mandarin.